Mildly Sensitive SkinNCT07874126
B5 Serum Instant Clinical Study
A study testing Topical skin soothing essence 1.0 and Topical skin soothing essence 2.0 in people with Mildly Sensitive Skin, run by ChinaNorm at 1 site in China.
Trial summary
The goal of this study is to explore the soothing effect of two test products within two hours after a single use by analyzing the changes in various indicators including clinical evaluation, non-invasive instrument measurement, image analysis and participant self-evaluation before and after product application. Read more about this study
- Who is it for?
- Ages 20 to 40 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Mildly Sensitive Skin
- What is being tested?
- Topical skin soothing essence 1.0 and Topical skin soothing essence 2.0
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 124 participants
- Where
- 1 siteChina
- Study dates
- 20 Mar 2026to 29 Sep 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 40 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- 1. Female Chinese subjects, aged 20-40 years old; 2. All skin types, with self-reported mild sensitive skin; 3. Self-reported tendency of easy skin flushing and erythema; 4. Full-face assessment by a dermatologist confirming the following skin characteristic:
- Skin redness grade ≥4 (Griffiths 10-point scale) 7-8 minutes after the red-inducing challenge; 5. Agree to refrain from using any cosmetics, skincare products, beauty devices, topical medications and cleansing products throughout the test period; 6. No participation in any clinical trials or cosmetic tests within the past 1 month; 7. No contraindications for test participation as assessed by a dermatologist; 8. In good general health during the study period; 9. Voluntarily sign the informed consent form and photo usage authorization form; 10. Agree to comply with all test requirements specified in the protocol.
Who cannot join
- 1. Pregnant or lactating women, or women planning to become pregnant during the test period; 2. Individuals unable to participate in the trial per the study schedule or with other conditions unsuitable for trial participation (e.g., deprived of rights by law or administrative order, under guardianship, receiving care from health or social welfare institutions, or undergoing emergency treatment); 3. Participants with skin diseases or allergic conditions at the test site (especially acne, rosacea, eczema); 4. Participants assessed by the investigator to have stable or progressively deteriorating diseases; 5. Immunocompromised participants; 6. Participants with a history of allergy to cosmetics, personal care products, or their ingredients; 7. Participants assessed by the investigator to have had excessive exposure to sunlight or ultraviolet radiation; 8. Participants with a history of photosensitivity or skin allergy; 9. Participants who regularly engage in water sports or nautical activities; 10. Participants with a regular sauna habit; 11. Subjects prone to allergies; 12. Participants with a medical history of cardiovascular or blood circulation disorders; 13. Participants with a history of skin cancer or malignant melanoma; 14. Participants who received aesthetic medical treatment or participated in other studies within 6 months prior to the study; 15. Participants who took antihistamines, antibiotics, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), or immunosuppressants within 6 months before the study.
Trial locations and contacts
1 site in 1 country.
China1 site
Shanghai China-norm Quality Technical Service Co., Ltd., Shanghai, Shanghai 200072, Shanghai,
Shanghai, Shanghai Municipality
About this study
The goal of this study is to explore the soothing effect of two test products within two hours after a single use by analyzing the changes in various indicators including clinical evaluation, non-invasive instrument measurement, image analysis and participant self-evaluation before and after product application.
The main questions it aims to answer are:
Read more
Can the two test products effectively relieve skin discomfort within two hours after a single use? What changes do multiple skin indicators show at different time points after the single application of the two test products? Researchers will adopt a single-center, split-face controlled study design. A total of about 124 healthy Chinese women aged 20-40 years will be enrolled and randomly divided into 2 groups with approximately 62 participants in each group.
Participants will:
Receive a single application of the assigned test product; Undergo skin indicator detection and clinical evaluation at scheduled time points within two hours after product application; Complete relevant self-evaluation questionnaires to record skin subjective feelings.
- Conditions
- Mildly Sensitive Skin
- Being tested
- Topical skin soothing essence 1.0, Topical skin soothing essence 2.0
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Topical skin soothing essence 1.0Other
Topical skin soothing essence 1.0, applied once to one side of the subject's face in this split-face study, to evaluate its soothing effect on induced skin redness.
Topical skin soothing essence 2.0Other
Topical skin soothing essence 2.0, applied once to one side of the subject's face in this split-face study, to evaluate its soothing effect on induced skin redness.
| Study group | Role | What they receive |
|---|---|---|
| Arm 1 | Experimental | Single topical application of Test Essence 1.0 on one side of the subject's face. Receives: Other: Topical skin soothing essence 1.0 |
| Arm 2 | Experimental | Single topical application of Test Essence 2.0 on one side of the subject's face. Receives: Other: Topical skin soothing essence 2.0 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in skin erythema measured by Mexameter® MX18
Skin erythema is measured by Mexameter® MX18 at baseline (BL). Compare the change of skin a* value between the side applied with Test Essence 1.0 and the side applied with Test Essence 2.0 in this split-face study, to evaluate the skin soothing effect on infrared-induced skin redness.
Measured: Baseline , post-induction (T0), 10 minutes, 1 hour and 2 hours after product application
Secondary outcomes (6)
Clinical skin redness score assessed by dermatologist
Dermatologist assesses skin redness using modified Griffiths 10-point scale (0.5 increments allowed) at Baseline , post-induction , 10 minutes, 1 hour and 2 hours after product application. The same dermatologist evaluates the same subject and is blinded to prior scores. Compare score changes between two sides of face.
Measured: Baseline , post-induction , 10 minutes, 1 hour and 2 hours after product application
Proportion of red area from VISIA 7 facial image analysis
Facial images are captured by VISIA7 under standard, cross-polarized and UV light. IPP software is used to analyze red area proportion at Baseline , post-induction , 10 minutes, 1 hour and 2 hours after product application. Compare red area proportion changes between two facial sides.
Measured: Baseline , post-induction , 10 minutes, 1 hour and 2 hours after product application
TiVi index (red blood cell concentration) measured by TiVi700
TiVi700 is used to detect red blood cell concentration (TiVi index) of bilateral cheeks at Baseline , post-induction , 10 minutes, 1 hour and 2 hours after product application. Compare TiVi index changes between two sides.
Measured: Baseline , post-induction , 10 minutes, 1 hour and 2 hours after product application
Skin temperature measured by FLUKE TIS60+ infrared camera
Facial skin temperature is acquired by FLUKE TIS60+ infrared camera at Baseline , post-induction , 5 minutes,10 minutes, 1 hour and 2 hours after product application. Compare skin temperature changes between two facial sides.
Measured: Baseline , post-induction , 5 minutes,10 minutes, 1 hour and 2 hours after product application
Subject self-assessment score of skin discomfort (0-4 scale)
Subjects complete self-assessment questionnaire for stinging, itching, burning and tightness (0-4 scale) at Post-induction , 10 minutes, 1 hour and 2 hours after product application. Higher scores mean more severe discomfort.
Measured: Post-induction , 10 minutes, 1 hour and 2 hours after product application
Subject questionnaire on product sensory experience
Subjects complete self-reported questionnaire regarding skin condition after product use at 10 minutes, 1 hour and 2 hours after product application.
Measured: 10 minutes, 1 hour and 2 hours after product application
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Oct 2026
- Study start20 Mar 2026
- Primary completion29 Mar 2026
- Study completion29 Sep 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mildly Sensitive SkinStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 124 participants (actual)
Sponsor and investigators
- Lead sponsor
- ChinaNorm
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07874126
- Sponsor's protocol ID
- C26005020
- Status last verified
- Oct 2026
- First submitted
- 8 Oct 2026
- Last updated
- 14 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- B5 Serum Instant Clinical Study
- ClinicalTrials.gov ID
- NCT07874126
- Acronym / sponsor ID
- C26005020
- Conditions
- Mildly Sensitive Skin
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 124 participants (actual)
- Lead sponsor
- ChinaNormIndustry (pharma, biotech, devices)
- Study start
- 20 Mar 2026 (actual)
- Primary completion
- 29 Mar 2026 (actual)
- Study completion
- 29 Sep 2026 (actual)
- First posted
- 14 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to explore the soothing effect of two test products within two hours after a single use by analyzing the changes in various indicators including clinical evaluation, non-invasive instrument measurement, image analysis and participant self-evaluation before and after product application.
The main questions it aims to answer are:
Can the two test products effectively relieve skin discomfort within two hours after a single use? What changes do multiple skin indicators show at different time points after the single application of the two test products? Researchers will adopt a single-center, split-face controlled study design. A total of about 124 healthy Chinese women aged 20-40 years will be enrolled and randomly divided into 2 groups with approximately 62 participants in each group.
Participants will:
Receive a single application of the assigned test product; Undergo skin indicator detection and clinical evaluation at scheduled time points within two hours after product application; Complete relevant self-evaluation questionnaires to record skin subjective feelings.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm 1 | Experimental | Other: Topical skin soothing essence 1.0Single topical application of Test Essence 1.0 on one side of the subject's face. |
| Arm 2 | Experimental | Other: Topical skin soothing essence 2.0Single topical application of Test Essence 2.0 on one side of the subject's face. |
Who may qualify
- Ages
- 20 to 40 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- 1. Female Chinese subjects, aged 20-40 years old; 2. All skin types, with self-reported mild sensitive skin; 3. Self-reported tendency of easy skin flushing and erythema; 4. Full-face assessment by a dermatologist confirming the following skin characteristic:
Key exclusion criteria (1 listed)
- 1. Pregnant or lactating women, or women planning to become pregnant during the test period; 2. Individuals unable to participate in the trial per the study schedule or with other conditions unsuitable for trial participation (e.g., deprived of rights by law or administrative order, under guardianship, receiving care from health or social welfare institutions, or undergoing emergency treatment); 3. Participants with skin diseases or allergic conditions at the test site (especially acne, rosacea, eczema); 4. Participants assessed by the investigator to have stable or progressively deteriorating diseases; 5. Immunocompromised participants; 6. Participants with a history of allergy to cosmetics, personal care products, or their ingredients; 7. Participants assessed by the investigator to have had excessive exposure to sunlight or ultraviolet radiation; 8. Participants with a history of photosensitivity or skin allergy; 9. Participants who regularly engage in water sports or nautical activities; 10. Participants with a regular sauna habit; 11. Subjects prone to allergies; 12. Participants with a medical history of cardiovascular or blood circulation disorders; 13. Participants with a history of skin cancer or malignant melanoma; 14. Participants who received aesthetic medical treatment or participated in other studies within 6 months prior to the study; 15. Participants who took antihistamines, antibiotics, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), or immunosuppressants within 6 months before the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Topical skin soothing essence 1.0Topical skin soothing essence 1.0, applied once to one side of the subject's face in this split-face study, to evaluate its soothing effect on induced skin redness. | Other | Arm 1 |
| Topical skin soothing essence 2.0Topical skin soothing essence 2.0, applied once to one side of the subject's face in this split-face study, to evaluate its soothing effect on induced skin redness. | Other | Arm 2 |
Primary outcome
Change in skin erythema measured by Mexameter® MX18
Time frame: Baseline , post-induction (T0), 10 minutes, 1 hour and 2 hours after product application
Skin erythema is measured by Mexameter® MX18 at baseline (BL). Compare the change of skin a* value between the side applied with Test Essence 1.0 and the side applied with Test Essence 2.0 in this split-face study, to evaluate the skin soothing effect on infrared-induced skin redness.
6 secondary outcomes
Clinical skin redness score assessed by dermatologist
Time frame: Baseline , post-induction , 10 minutes, 1 hour and 2 hours after product application
Proportion of red area from VISIA 7 facial image analysis
Time frame: Baseline , post-induction , 10 minutes, 1 hour and 2 hours after product application
TiVi index (red blood cell concentration) measured by TiVi700
Time frame: Baseline , post-induction , 10 minutes, 1 hour and 2 hours after product application
Skin temperature measured by FLUKE TIS60+ infrared camera
Time frame: Baseline , post-induction , 5 minutes,10 minutes, 1 hour and 2 hours after product application
Subject self-assessment score of skin discomfort (0-4 scale)
Time frame: Post-induction , 10 minutes, 1 hour and 2 hours after product application
Subject questionnaire on product sensory experience
Time frame: 10 minutes, 1 hour and 2 hours after product application
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Mildly Sensitive Skin
Not yet recruitingPhase 2
A Study of JYP0066 Cream in Mild-to-Moderate Atopic Dermatitis
Atopic Dermatitis (AD)
Recruiting
Double-blind, Randomized, Non-inferiority Trial in Atopic Dermatitis: Comparison of Lipikar Balm and Relipid+ Balm in the Treatment of Mild to Moderate Atopic Dermatitis in Children and Adults
Atopic Dermatitis, Emollients
Recruiting
Safety and Efficacy of Skincare Products for Managing Mild to Moderate Acne in Individuals With Sensitive Skin
Acne
Not yet recruitingPhase 4
Azithromycin in Atopic Dermatitis
Atopic Dermatitis
RecruitingPhase 2
A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis
Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Topical skin soothing essence 1.0 and Topical skin soothing essence 2.0 in people with Mildly Sensitive Skin, run by ChinaNorm at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in skin erythema measured by Mexameter® MX18 (time frame: Baseline , post-induction (T0), 10 minutes, 1 hour and 2 hours after product application). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Oct 2026.